For long-term studies, this can sometimes present practical challenges, especially if high frequency of administration is required
Most common adverse events at all doses: Nausea (3355%, dose-related) Vomiting (1335%) Decreased appetite (1528%) Constipation or diarrhea (1020%) Injection-site reaction (510%) Dose-related dysesthesia signal: The TRIUMPH-4 trial identified a dose-related dysesthesia (nerve-tingling, paresthesia) signal: This is the most-flagged trial-level safety signal for retatrutide and the reason community doses cluster at 2-4 mg/week well below where the dysesthesia signal becomes prominent
It also comes with potential side effects, albeit rare ones, including breathing issues (with spray products) and skin inflammation in some people
Phospholipids are essential for maintaining the integrity of your cell membranes
The metabolic and pharmacokinetic differences between species are relevant, and Phase 1 human safety trials have not been completed for BPC-157
This antioxidant has also been associated with skin health and a radiant complexion